Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230051 | 1.00 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8491815 | 1.00 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28156652 | 0.98 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL994487 | 0.98 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28155972 | 0.98 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23638927 | 0.91 | NPC1 (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1163022 | 0.90 | MAPK1 (0.59) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1163023 | 0.90 | MAPK1 (0.59) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28280152 | 0.90 | MAPK1 (0.59) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL594567 | 0.90 | NPC1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | claimed |
| EP-3612174-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION | INST NAT SANTE RECH MED (FR) | 2023-02-22 | — | — | EP | claimed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| EP-1188744-B1 | Process for producing optically active 1H-3-aminopyrrolidine and derivatives thereof | MITSUBISHI CHEM CORP (JP) | 2005-11-02 | — | — | EP | claimed |
| US-5686482-A | DOPAMINE RECEPTOR ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | claimed |
| CN-1147248-A | N- (3-pyrrolidinyl) benzamide derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1997-04-09 | — | — | CN | claimed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | claimed |
| US-4049821-A | 3-AMINO-PYRROLIDINYL-BENZAMIDE | A. H. ROBINS COMPANY, INC. (US) | 1977-09-20 | — | — | US | claimed |
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240083844-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022262854-A1 | CLY SERIES COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF DRUGS | 南京韦尔优众医药有限公司 | 2022-12-22 | — | — | WO | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| US-4073796-A | ANTIEMETIC | A. H. ROBINS COMPANY, INC. (US) | 1978-02-14 | — | — | US | disclosed |
| US-4049821-A | 3-AMINO-PYRROLIDINYL-BENZAMIDE | A. H. ROBINS COMPANY, INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-4039678-A | N-(SUBSTITUTED-3-PYRROLIDINYL)-1-NAPHTHALENE CARBOXAMIDES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-08-02 | — | — | US | disclosed |
| US-4002757-A | ANTIEMETIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-01-11 | — | — | US | disclosed |
| US-3966957-A | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-06-29 | — | — | US | disclosed |
| US-3963745-A | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083844-A1 | KINASE INHIBITORS AND USES THEREOF | MINK1, PTK2, PLK4 | MEN1 505/4885KMT2A 633/4885NPC1 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.